Nateglinide
CAS No. 105816-04-4
Nateglinide ( A-4166; SDZ-DJN 608 )
Catalog No. M10264 CAS No. 105816-04-4
Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM).
Purity : >98%(HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
10MG | 37 | In Stock |
|
25MG | 75 | In Stock |
|
50MG | 133 | In Stock |
|
100MG | 224 | In Stock |
|
200MG | 323 | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNateglinide
-
NoteResearch use only, not for human use.
-
Brief DescriptionNateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM).
-
DescriptionNateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those nave to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound.
-
SynonymsA-4166; SDZ-DJN 608
-
PathwayCell Cycle/DNA Damage
-
TargetPotassium Channel
-
RecptorPotassium Channel; PPARγ
-
Research AreaCardiovascular Disease
-
Indication——
Chemical Information
-
CAS Number105816-04-4
-
Formula Weight317.42
-
Molecular FormulaC19H27NO3
-
Purity>98%(HPLC)
-
SolubilityEthanol: 63 mg/mL (198.47 mM); DMSO: 63 mg/mL (198.47 mM)
-
SMILESO=C(O)[C@@H](CC1=CC=CC=C1)NC([C@H]2CC[C@H](C(C)C)CC2)=O
-
Chemical Name(R)-2-((1r,4R)-4-isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Hu S, et al. J Pharmacol Exp Ther. 2000 May;293(2):444-52.
molnova catalog
related products
-
Potassium Channel Ac...
Potassium Channel Activator 1 can be used in studies about the treatment of disorders or conditions wherein the dopaminergic system is disrupted such as mood disorders ADHD, schizophrenia, and other psychotic states.
-
E-4031 dihydrochlori...
E-4031 is a class III antiarrhythmic agent that binds to Kv11.1 (hERG) and blocks the rapid delayed-rectifier K+ current (IKr).
-
SKA31
SKA 31 is an activator of KCa3.1 and KCa2 channels (EC50s: 260 2900 2900 nM for KCa3.1 KCa2.1 and KCa2.2 respectively).